Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Geert J. C. M. Kolvenbag"'
Autor:
James E. Montie, C.J. Tyrrell, D. M. A. Wallace, Kevin Carroll, Peter Iversen, Teuvo L.J. Tammela, Bo-Eric Persson, Ira W. Klimberg, Gerald W. Chodak, Manfred P. Wirth, Donald Gleason, Geert J. C. M. Kolvenbag, Karl P.J. Delaere, Sigmund Vaage, David G. McLeod, William A. See, Olavi Lukkarinen
Publikováno v:
Journal of Urology. 168:429-435
Purpose: We determine the efficacy and tolerability of bicalutamide as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with clinically localized or locally advanced prostate cancer.Materials and Methods: Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::175ee6a678742c5531a679960c9b406d
https://doi.org/10.1016/s0022-5347(05)64652-6
https://doi.org/10.1016/s0022-5347(05)64652-6
Autor:
Paul Wissel, Geert J. C. M. Kolvenbag, Blake Lee Neubauer, Joanne Waldstreicher, Donald L. Trump
Publikováno v:
Urology. 57:64-67
This article summarizes discussions of the importance of androgens and androgen antagonists in the genesis of prostate cancer. These discussions occurred at a recent symposium on prostate cancer chemoprevention sponsored by the National Cancer Instit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c291ed45c10e00eda4a9518a06fb0e92
https://doi.org/10.1016/s0090-4295(00)00943-2
https://doi.org/10.1016/s0090-4295(00)00943-2
Autor:
Geert J. C. M. Kolvenbag
Publikováno v:
The Prostate Journal. 3:2-13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45350e94568569d75e4d2e7c01394ced
https://doi.org/10.1046/j.1525-1411.2001.003001002.x
https://doi.org/10.1046/j.1525-1411.2001.003001002.x
Autor:
Michael F. Sarosdy, Mark S. Soloway, Peter M. Venner, Norman L. Block, Geert J. C. M. Kolvenbag, Julie Schellenger, Rooholloh Sharifi, A. Lynn Patterson, Paul F. Schellhammer, Nicholas J. Vogelzang
Publikováno v:
The Prostate Journal. 2:137-145
Objectives: We performed an exploratory analysis to determine whether there was a difference between two antiandrogen-plus-luteinizing hormone-releasing hormone analogs (LHRHas) combinations in patients with minimal or extensive disease. Materials an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46d66a11b788484b7e823e2bc77cf534
https://doi.org/10.1046/j.1525-1411.2000.23003.x
https://doi.org/10.1046/j.1525-1411.2000.23003.x
Autor:
Michael F. Sarosdy, Mark S. Soloway, David G. McLeod, Peter Venner, A. Lynn Patterson, R. Patrick Kelley, Geert J. C. M. Kolvenbag, Rooholloh Sharifi, Paul F. Schellhammer, Nicholas J. Vogelzang, Norman L. Block
Publikováno v:
The Prostate. 40:218-224
BACKGROUND Black race has been associated with a significantly increased risk of prostate cancer mortality. This exploratory analysis investigated the effect of race on the clinical outcome of combined androgen blockade (CAB). METHODS Data for analys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::835d165278ec06900642ebc6b79b2669
https://doi.org/10.1002/(sici)1097-0045(19990901)40:4<218::aid-pros2>3.0.co
https://doi.org/10.1002/(sici)1097-0045(19990901)40:4<218::aid-pros2>3.0.co
Autor:
Glenn J. Bubley, Robin Joyce, Mary-Ellen Taplin, Geert J. C. M. Kolvenbag, Mary Anne Fenton, Steve Balk, Michael Constantine, William C. DeWolf, Paola Rode, Lisa Gaynes
Publikováno v:
Journal of Urology. 159:149-153
A pilot study of the antiandrogen bicalutamide at 150 mg. a day for androgen independent prostate cancer was performed. This study was based on the possibility that androgen independent cases might display responses to additional hormonal agents.The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9de0bd0e6acfd7db0b692565e8d3c63
https://doi.org/10.1016/s0022-5347(01)64039-4
https://doi.org/10.1016/s0022-5347(01)64039-4
Autor:
Paul F. Schellhammer, Roohollah Sharifi, Norman L. Block, Mark S. Soloway, Peter M. Venner, A. Lynn Patterson, Michael F. Sarosdy, Nicholas J. Vogelzang, Yusong Chen, Geert J. C. M. Kolvenbag, null for the CASODEX Combination Study G
Publikováno v:
Cancer. 78:2164-2169
BACKGROUND A randomized, multicenter trial, double-blind for antiandrogen therapy, compared the antiandrogens bicalutamide and flutamide, each combined with luteinizing hormone–releasing hormone analogue therapy (LHRH-A) in 813 patients with Stage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1735a1e753b8106512bb8235521cec71
https://doi.org/10.1002/(sici)1097-0142(19961115)78:10<2164::aid-cncr18>3.0.co
https://doi.org/10.1002/(sici)1097-0142(19961115)78:10<2164::aid-cncr18>3.0.co
Autor:
Peter Venner, Paul F. Schellhammer, Norman L. Block, Michael F. Sarosdy, A.Lynn Patterson, Mark S. Soloway, Nicholas J. Vogelzang, Geert J. C. M. Kolvenbag, Julie Jones, Roohollah Sharifi
Publikováno v:
Urology. 47:54-60
Objectives. To review the outcome of therapy with maximal androgen blockade and compare the efficacy and safety of bicalutamide and flutamide, each used in combination with luteinizing hormone-releasing hormone analogue (LHRH-A) therapy, in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1da821bd85bab1708ad8a8f54c047496
https://doi.org/10.1016/s0090-4295(96)80010-0
https://doi.org/10.1016/s0090-4295(96)80010-0
Autor:
William A, See, Manfred P, Wirth, David G, McLeod, Peter, Iversen, Ira, Klimberg, Donald, Gleason, Gerald, Chodak, James, Montie, Chris, Tyrrell, D M A, Wallace, Karl P J, Delaere, Sigmund, Vaage, Teuvo L J, Tammela, Olavi, Lukkarinen, Bo-Eric, Persson, Kevin, Carroll, Geert J C M, Kolvenbag
Publikováno v:
The Journal of urology. 168(2)
We determine the efficacy and tolerability of bicalutamide as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with clinically localized or locally advanced prostate cancer.This international program consist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::08e2e97932af5b080b0bc628119795dc
https://pubmed.ncbi.nlm.nih.gov/12656893
https://pubmed.ncbi.nlm.nih.gov/12656893
Publikováno v:
Urology. 58(2 Suppl 1)
Nonsteroidal antiandrogens are generally used in conjunction with castration as combined androgen blockade. However, the changing profile of patients with prostate cancer has made monotherapy with a nonsteroidal antiandrogen an attractive alternative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa1832bf46ac22fa7fa89e0fecca1d6a
https://pubmed.ncbi.nlm.nih.gov/11502439
https://pubmed.ncbi.nlm.nih.gov/11502439